A preregistered propensity score-matched cohort study across approximately 300,000 matched pairs, presented by Ralf Ludwig with Florian Thaqi, Katja Bieber,
A prospective single-centre observational series of omalizumab in paediatric chronic inducible urticaria, reported by Inna Larkova with Valeryi Mukhortykh, Diana
An assessment of where endotype-directed prescribing now stands following two regulatory approvals, presented by Martin Metz (Berlin, Germany), who also
A guideline-focused teaching lecture covering classification, diagnostic work-up and treat-to-target management, delivered by Krisztina Steuer-Hajdu (Debrecen, Hungary) within the Updates
An expert overview of pathomechanism and the emerging therapeutic pipeline, delivered by Ana Maria Giménez-Arnau (Barcelona, Spain), who also co-chaired
An expert overview of pathomechanism and the emerging therapeutic pipeline, delivered by Ana Maria Giménez-Arnau (Barcelona, Spain), who also co-chaired
SETTING THE SCENE JAK1 inhibition in AD has been validated at the clinical endpoint level, but the cellular mechanism in
SETTING THE SCENE Both JAK1 inhibitors and dupilumab produce impressive efficacy on treatment, but what happens after planned or forced
SETTING THE SCENE Facial AD in children with skin of colour is a sensitive therapeutic niche: topical corticosteroids are often
SETTING THE SCENE The 2% crisaborole formulation is one of the main non-steroidal options for pediatric mild-to-moderate AD, but its